BioWorld News’ Post

Today we released updated medium-term financial guidance following the recent completion of our acquisition of ABL Europe, as well as an update on trading for the year ended 31 December 2023, highlighting our progress towards delivering our pure-play CDMO strategy.   Highlights from the announcement include:   🔹 Three-year revenue CAGR increased to more than 35%, up from prior guidance of more than 30%   🔹  Projected FY2024 revenue range of £126 million to £134 million, reflecting the successful integration of ABL Europe and anticipated growth from new and existing client programmes   🔹 FY2023 revenues and EBITDA expected to be in line with guidance provided at the Interim Results   Read more in our release here: https://lnkd.in/edUmRZXp   #CDMO #CellAndGeneTherapy #ViralVectors

Feel overwhelmed by the data deluge in NGS reports? Our guide offers a beacon of clarity, breaking down complex metrics and guiding you through each step of the report. It’s an essential resource for anyone seeking to harness the full potential of NGS technology in their field. Demystify NGS data with our expert guide: https://okt.to/fT4tNR #nextgenerationsequencing #sangersequencing

Exciting News!  Monday, September 23, NPR's Morning Edition has scheduled a story on FRAXA highlighting the progress of research aimed at Fragile X treatments. The segment will include a special feature on the Mazzola family's personal journey and experience with Zatolmilast, an investigational new drug currently in late stage clinical trials. Be sure to tune in! **Please note, if there’s a major news story, the segment may get bumped to another day — but we’re hopeful it will air as planned!  #FragileX #FX #NPR #MorningEdition #ClinicalTrials

Thoughts on this? >> Autoimmune CAR-T data dump: Kyverna, Cabaletta shares fall after unveiling early-stage results >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #productmarketing #pharma #biotech

You won't want to miss this! 🤩 Next week, our digital strategies team will share an exciting overview of our new #STOX digital platform for our #SteroidToxicity assessments. Join our webinar on Thursday, March 14 at 11am ET for a front row seat to how to access all assessments, score each visit and bulk data upload with real-time #DataVisualization of steroid-toxicity scores. #STOX #SteritasGTI

Thoughts on this? >> Autoimmune CAR-T data dump: Kyverna, Cabaletta shares fall after unveiling early-stage results >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #healthcare #pharmaceutical #productmarketing

You won't want to miss this! 🤩 Next week, our digital strategies team will share an exciting overview of our new #STOX digital platform for our #SteroidToxicity assessments. Join our webinar on Thursday, March 14 at 11am ET for a front row seat to how to access all assessments, score each visit and bulk data upload with real-time #DataVisualization of steroid-toxicity scores. #STOX #SteritasGTI

For over fifty years, hemophilia A and B have primarily been treated with frequent intravenous infusions. The recent approval of BEQVEZ by the US FDA for adults with hemophilia B marks a significant advancement. Pfizer is further advancing in the hemophilia market with the expected approval of marstacimab by the end of the year. If approved in the US and EU, marstacimab will be the first once-weekly subcutaneous treatment for hemophilia B and the first flat-dose option for hemophilia A or B. This treatment option is particularly advantageous for patients lacking reliable vascular access, potentially improving convenience and compliance. #Marstacimab offers a promising alternative to current treatments for hemophilia A or B, showing potential clinical benefits and enhancing patient care by remaining effective even in the presence of inhibitors, unlike traditional factor replacement products. Novo Nordisk's concizumab, branded as ALHEMO in authorized markets such as Canada, Australia, Switzerland, and Japan, is expected to face competitive pressure from Pfizer in this evolving landscape. Unlock Expert Insights and In-Depth Analysis Exclusively with DelveInsight Business Research LLP at European Hematology Association 2024 @ https://lnkd.in/gGeqCskd #HemophiliaA #HemophiliaB #BEQVEZ #GeneTherapy #Marstacimab #Pfizer #FDAApproval #SubcutaneousTreatment #PatientCare #Concizumab #ALHEMO #NovoNordisk

Explore the benefits of our Preclarus enterprise and information management portal, which substantially minimizes queries in #clinicaltrial data sets, reduces site burden, accelerates data lock and results in significant time savings. Download the case study ➠ https://bit.ly/44ezWpF

Read our latest Q&A with Oncocyte Corporation ($OCX) CFO Andrea S. James as she sheds light on her personal career path and the experiences that led to her senior role with the molecular diagnostics technology company. https://bit.ly/3SXb1Ua #investors #oncocyte #stockstowatch #stocksinnews #investors #daytrader #PrismMarketView #PrismMediaWire #PrismDigitalMedia